UCB US (@UCBUSA) header
UCB US (@UCBUSA) profile picture

Official U.S. Twitter for UCB, a global biopharmaceutical company. We are dedicated to putting patients at the heart of everything we do.

Atlanta, Georgia
Joined February 2018
Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)Photo by UCB US (@UCBUSA)
FOR MEDIA: UCB is announcing U.S. FDA approval of a new autoinjector administration option, providing another option for adults living with generalized myasthenia gravis (gMG). Learn more: prn.to/3WtUv2l
135
Meet #WearItOut, created with and for people living with HS, psoriasis and PsA. Learn More: ucb-usa.com/stories-media/UC…
1
193
FOR MEDIA: New data presented at #AANEM and the MGFA Scientific Session highlight UCB's commitment to advancing treatment options for people living with generalized myasthenia gravis (gMG): ucb-usa.com/stories-media/UC…
231
FOR MEDIA: UCB announces @US_FDA Breakthrough Therapy Designation for a potential treatment for pregnant women living with antiphospholipid syndrome (APS). Learn more: ucb-usa.com/stories-media/UC…
298
📢 FOR MEDIA ONLY | UCB shares new data in psoriatic arthritis. 🔗Click here to learn more: ucbusa.news/4wGj9dT
3
631
Congratulations to our very own Jeannette Novatski!👏👏👏
We conclude our #WorkingforCures Champion series with Jeannette Novatski from @UCBUSA. Jeannette is a member of @npcnow and helps shape the national health policy research agenda, ensuring that research is rigorous, stakeholder-aligned and impactful across the health care ecosystem. Amazing work, Jeanette, and congratulations.
355
For Media: New data presented at #AANAM highlight the real-world impact of epilepsy beyond seizures, showing how sleep disruption and prolonged seizures can substantially affect daily functioning, work productivity, and quality of life for patients and caregivers. Learn more: ucbusa.news/3OitWtx
1
1
305
For Media: UCB announces new clinical data from its generalized myasthenia gravis portfolio at the 2026 American Academy of Neurology Annual Meeting. #AANAM ucbusa.news/3QC5Das
267
FOR MEDIA: Today at #AAD2026, UCB presents new data in moderate-to-severe plaque psoriasis. Learn more: ucbusa.news/4sFFo1c
240
FOR MEDIA: Today, UCB shares new hidradenitis suppurativa data at #AAD2026. Learn more: ucbusa.news/4lVshpV
1
259
FOR MEDIA: UCB shares leading Scientific research and advances with 21 abstracts at American Epilepsy Society Annual Meeting in Atlanta. Learn More: #AES2025

361
We’re partnering with @CitizenHealthX to advance data and technology that improve care for people living with epilepsy and rare diseases. Together, we aim to accelerate research, close gaps in understanding, and drive better outcomes. Learn more: bit.ly/4phJ2wC
1
259
FOR MEDIA: @US_FDA approves new treatment option for Thymidine Kinase 2 deficiency (#TK2d), with symptom onset on or before 12 years. Learn More:

346
FOR MEDIA: Today UCB announces three-year data in moderate-to-severe #hidradenitissuppurativa at #SHSA2025 in Nashville. Learn more:

413
For media: UCB unveils new data at the 2025 AANEM Annual Meeting and MGFA Scientific Session #AANEMinSanFran Learn More:tinyurl.com/ucb-usa
343
FOR MEDIA: UCB presents three-year data in #psoriaticarthritis and axial spondyloarthritis (#axSpA) at #ACR25 in Chicago. Learn More: tinyurl.com/ucbusa
1
362
For Media: UCB announces long-term data on the treatment of seizures in children and adults living with Lennox-Gastaut syndrome in open-label extension study published in Epilepsy & Behavior.

256